Ixazomib Phase III Trial Discontinued in AL Amyloidosis

Gina Columbus @ginacolumbusonc

Published: Thursday, Jun 06, 2019

Phil Rowlands, PhD

Ixazomib (Ninlaro) in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared with standard therapy in patients with relapsed/refractory systemic light-chain (AL) amyloidosis, missing one of two primary endpoints in the phase III TOURMALINE-AL1 trial and leading to discontinuation of the study.¹

Ixazomib is currently approved by the FDA in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received ≥1 prior therapy.

References

Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis. Takeda Pharmaceutical Company. Published June 5, 2019. https://bit.ly/2Xu2CIX. Accessed June 5, 2019.
Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605. doi: 10.1182/blood-2017-03-771220.

... to read the full story

To Read the Full Story

View Other News on Hematologic Oncology

View Conference Coverage

2019 State of the Science Summit on Hematologic Malignancies in Pittsburgh

2019 State of the Science Summit on Hematologic Malignancies in Seattle

15th International Conference on Malignant Lymphoma

2019 European Hematology Association Congress

Online CME Activities

Title	Expiration Date	CME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of Immunotherapy	Aug 13, 2019	1.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell Therapy	Aug 30, 2019	1.5